Indivior Pharmaceuticals

INDVNasdaq United Kingdom Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$4.194 B

$35.53 +1.86%

Close of 21 Sept 2026

Revenue

$1.24B

#1403 by revenue

Earnings

$210.0M

#980 by earnings

Shares outstanding

118,013,649

Latest filing cover page

P/E ratio

20.0

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#60Parabilis MedicinesPBLS$4.50B
#61Genmab A/SGMAB$4.46B
#62Indivior PharmaceuticalsINDV$4.19B
#63AbCellera BiologicsABCL$4.10B
#64Amylyx PharmaceuticalsAMLX$4.06B

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Indivior Pharmaceuticals, worth $54.4K. Grants and option exercises are excluded.

Woodrow D. AndersonChief Accounting Officer$54.4K
1,500 shares at $36.28 on 5 Aug 2026 · filed 5 Aug 2026

What if Indivior Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$256,490.37

Per share 7,219× higher

Bitcoin $1.72T

$14,570.66

Per share 410× higher

Nvidia $5.48T

$46,426.91

Per share 1,307× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for Indivior Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.